The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Neurological Drugs Market Research Report 2024

Global Neurological Drugs Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1744078

No of Pages : 116

Ask Your Query

Synopsis
Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system, mainly manifested in sensory, motor, consciousness, and autonomic dysfunction.

Global Neurological Drugs market is projected to reach US$ 194500 million in 2029, increasing from US$ 118000 million in 2022, with the CAGR of 7.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neurological Drugs market research.

Key manufacturers engaged in the Neurological Drugs industry include Pfizer, Ely Lilly, Actavis, Mylan, Randox, Intellipharmaceutics, Astrazeneca, Lundbeck and Allergan, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Neurological Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Neurological Drugs market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Neurological Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Pfizer
  • Ely Lilly
  • Actavis
  • Mylan
  • Randox
  • Intellipharmaceutics
  • Astrazeneca
  • Lundbeck
  • Allergan
  • GSK
  • Otsuka Pharmaceutical
  • Takeda
  • NHU Group
  • Shionogi
  • APOTEX
  • North China Pharmaceutical
  • Harbin Pharmaceutical Co., Ltd.
  • Lukang Pharmaceutical
  • Kelun Pharmaceutical
  • Kehua Biology

Segment by Type

  • Non-prescription drugs
  • Prescription

Segment by Application

  • Hospital
  • Clinic

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Neurological Drugs report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Neurological Drugs Market Overview
1.1 Product Overview and Scope of Neurological Drugs
1.2 Neurological Drugs Segment by Type
1.2.1 Global Neurological Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Non-prescription drugs
1.2.3 Prescription
1.3 Neurological Drugs Segment by Application
1.3.1 Global Neurological Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Neurological Drugs Market Size Estimates and Forecasts
1.4.1 Global Neurological Drugs Revenue 2018-2029
1.4.2 Global Neurological Drugs Sales 2018-2029
1.4.3 Global Neurological Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Neurological Drugs Market Competition by Manufacturers
2.1 Global Neurological Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Neurological Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Neurological Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Neurological Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Neurological Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurological Drugs, Product Type & Application
2.7 Neurological Drugs Market Competitive Situation and Trends
2.7.1 Neurological Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neurological Drugs Players Market Share by Revenue
2.7.3 Global Neurological Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neurological Drugs Retrospective Market Scenario by Region
3.1 Global Neurological Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Neurological Drugs Global Neurological Drugs Sales by Region: 2018-2029
3.2.1 Global Neurological Drugs Sales by Region: 2018-2023
3.2.2 Global Neurological Drugs Sales by Region: 2024-2029
3.3 Global Neurological Drugs Global Neurological Drugs Revenue by Region: 2018-2029
3.3.1 Global Neurological Drugs Revenue by Region: 2018-2023
3.3.2 Global Neurological Drugs Revenue by Region: 2024-2029
3.4 North America Neurological Drugs Market Facts & Figures by Country
3.4.1 North America Neurological Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Neurological Drugs Sales by Country (2018-2029)
3.4.3 North America Neurological Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neurological Drugs Market Facts & Figures by Country
3.5.1 Europe Neurological Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Neurological Drugs Sales by Country (2018-2029)
3.5.3 Europe Neurological Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurological Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Neurological Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Neurological Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Neurological Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Neurological Drugs Market Facts & Figures by Country
3.7.1 Latin America Neurological Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Neurological Drugs Sales by Country (2018-2029)
3.7.3 Latin America Neurological Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Neurological Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurological Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Neurological Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Neurological Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neurological Drugs Sales by Type (2018-2029)
4.1.1 Global Neurological Drugs Sales by Type (2018-2023)
4.1.2 Global Neurological Drugs Sales by Type (2024-2029)
4.1.3 Global Neurological Drugs Sales Market Share by Type (2018-2029)
4.2 Global Neurological Drugs Revenue by Type (2018-2029)
4.2.1 Global Neurological Drugs Revenue by Type (2018-2023)
4.2.2 Global Neurological Drugs Revenue by Type (2024-2029)
4.2.3 Global Neurological Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Neurological Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Neurological Drugs Sales by Application (2018-2029)
5.1.1 Global Neurological Drugs Sales by Application (2018-2023)
5.1.2 Global Neurological Drugs Sales by Application (2024-2029)
5.1.3 Global Neurological Drugs Sales Market Share by Application (2018-2029)
5.2 Global Neurological Drugs Revenue by Application (2018-2029)
5.2.1 Global Neurological Drugs Revenue by Application (2018-2023)
5.2.2 Global Neurological Drugs Revenue by Application (2024-2029)
5.2.3 Global Neurological Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Neurological Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Neurological Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Ely Lilly
6.2.1 Ely Lilly Corporation Information
6.2.2 Ely Lilly Description and Business Overview
6.2.3 Ely Lilly Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Ely Lilly Neurological Drugs Product Portfolio
6.2.5 Ely Lilly Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Corporation Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Actavis Neurological Drugs Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Mylan Neurological Drugs Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Randox
6.5.1 Randox Corporation Information
6.5.2 Randox Description and Business Overview
6.5.3 Randox Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Randox Neurological Drugs Product Portfolio
6.5.5 Randox Recent Developments/Updates
6.6 Intellipharmaceutics
6.6.1 Intellipharmaceutics Corporation Information
6.6.2 Intellipharmaceutics Description and Business Overview
6.6.3 Intellipharmaceutics Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Intellipharmaceutics Neurological Drugs Product Portfolio
6.6.5 Intellipharmaceutics Recent Developments/Updates
6.7 Astrazeneca
6.6.1 Astrazeneca Corporation Information
6.6.2 Astrazeneca Description and Business Overview
6.6.3 Astrazeneca Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Astrazeneca Neurological Drugs Product Portfolio
6.7.5 Astrazeneca Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Corporation Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Lundbeck Neurological Drugs Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
6.9 Allergan
6.9.1 Allergan Corporation Information
6.9.2 Allergan Description and Business Overview
6.9.3 Allergan Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Allergan Neurological Drugs Product Portfolio
6.9.5 Allergan Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 GSK Neurological Drugs Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 Otsuka Pharmaceutical
6.11.1 Otsuka Pharmaceutical Corporation Information
6.11.2 Otsuka Pharmaceutical Neurological Drugs Description and Business Overview
6.11.3 Otsuka Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Otsuka Pharmaceutical Neurological Drugs Product Portfolio
6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Corporation Information
6.12.2 Takeda Neurological Drugs Description and Business Overview
6.12.3 Takeda Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Takeda Neurological Drugs Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 NHU Group
6.13.1 NHU Group Corporation Information
6.13.2 NHU Group Neurological Drugs Description and Business Overview
6.13.3 NHU Group Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 NHU Group Neurological Drugs Product Portfolio
6.13.5 NHU Group Recent Developments/Updates
6.14 Shionogi
6.14.1 Shionogi Corporation Information
6.14.2 Shionogi Neurological Drugs Description and Business Overview
6.14.3 Shionogi Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Shionogi Neurological Drugs Product Portfolio
6.14.5 Shionogi Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Corporation Information
6.15.2 APOTEX Neurological Drugs Description and Business Overview
6.15.3 APOTEX Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 APOTEX Neurological Drugs Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 North China Pharmaceutical
6.16.1 North China Pharmaceutical Corporation Information
6.16.2 North China Pharmaceutical Neurological Drugs Description and Business Overview
6.16.3 North China Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.16.4 North China Pharmaceutical Neurological Drugs Product Portfolio
6.16.5 North China Pharmaceutical Recent Developments/Updates
6.17 Harbin Pharmaceutical Co., Ltd.
6.17.1 Harbin Pharmaceutical Co., Ltd. Corporation Information
6.17.2 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Description and Business Overview
6.17.3 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolio
6.17.5 Harbin Pharmaceutical Co., Ltd. Recent Developments/Updates
6.18 Lukang Pharmaceutical
6.18.1 Lukang Pharmaceutical Corporation Information
6.18.2 Lukang Pharmaceutical Neurological Drugs Description and Business Overview
6.18.3 Lukang Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Lukang Pharmaceutical Neurological Drugs Product Portfolio
6.18.5 Lukang Pharmaceutical Recent Developments/Updates
6.19 Kelun Pharmaceutical
6.19.1 Kelun Pharmaceutical Corporation Information
6.19.2 Kelun Pharmaceutical Neurological Drugs Description and Business Overview
6.19.3 Kelun Pharmaceutical Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Kelun Pharmaceutical Neurological Drugs Product Portfolio
6.19.5 Kelun Pharmaceutical Recent Developments/Updates
6.20 Kehua Biology
6.20.1 Kehua Biology Corporation Information
6.20.2 Kehua Biology Neurological Drugs Description and Business Overview
6.20.3 Kehua Biology Neurological Drugs Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Kehua Biology Neurological Drugs Product Portfolio
6.20.5 Kehua Biology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurological Drugs Industry Chain Analysis
7.2 Neurological Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurological Drugs Production Mode & Process
7.4 Neurological Drugs Sales and Marketing
7.4.1 Neurological Drugs Sales Channels
7.4.2 Neurological Drugs Distributors
7.5 Neurological Drugs Customers
8 Neurological Drugs Market Dynamics
8.1 Neurological Drugs Industry Trends
8.2 Neurological Drugs Market Drivers
8.3 Neurological Drugs Market Challenges
8.4 Neurological Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock